Oaktree Acquisition II filed an investor presentation highlighting its proposed merger with Alvotech Holdings, a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines.
The SPAC has scheduled a June 7 meeting for shareholders to vote on the deal.
As announced in December, the combination is expected to deliver gross proceeds to Alvotech in excess of $450 million. The deal has an implied enterprise value of $2.25 billion.
If approved, the combined company is expected to trade on the Nasdaq under ALVO. Read more.
